This week, small shrews make a big difference in dry eye disease, Allergan sues Imprimis for $7 million but wins much less and an IOP-lowering gene therapy shows promise in primates. Source: AAO
Investigators assessed the effects of a patient-information video on anxiety levels before cataract surgery. Source: AAO
This prospective case series evaluates the feasibility and usefulness of intraoperative OCT for uveitis-related vitreoretinal surgeries. Source: AAO
This phase 3 randomized controlled trial assessed the efficacy of eculizumab, a terminal complement inhibitor, for reducing relapse frequency in aquaporin-4–positive neuromyelitis optica spectrum disorder (NMOSD). Source: AAO
In this study, researchers analyzed patient wait times during visits to a glaucoma clinic and identified opportunities for additional patient engagement. Source: AAO
This paper reports the validity and reliability of a new app for calculating the gaze angle in patients with strabismus. Source: AAO
This week, a retired competitive agility dog dons prescription eyewear, botulism toxin becomes a first-line treatment for blepharospasm and GenSight’s experimental gene therapy for Leber’s neuropathy shows sustained benefits at 2 years. Source: AAO
Investigators report the use of a topical tacrolimus monotherapy for vernal keratoconjunctivitis (VKC). Source: AAO
This paper characterizes the clinical and neuroimaging findings in severe cases of myelin oligodendrocyte glycoprotein (MOG) antibody–positive bilateral recurrent optic neuritis (ON). Source: AAO
Aflibercept is now an approved treatment for all stages of diabetic retinopathy (DR), making it the only anti-VEGF agent with two dosing options for DR. Source: AAO